Reported positive six-month data from ADVANCED-2 trial of TARA-002 in patients with NMIBC Completed approximately $100 million public offering, extending runway into 2027 Initial data from 12-month ev ...

In December 2024, the Company reported positive interim results from its ongoing Phase 2 open-label ADVANCED-2 trial in in ...

"In addition, we expect to begin the pivotal THRIVE-3 study of intravenous (IV) Choline Chloride in the first half of 2025.